Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2018

01-12-2018 | Hepatitis B (J Lim, Section Editor)

Implications of Circulating Hepatitis B Virus RNA Levels in Assessment of Response to Antiviral Therapy

Authors: Tianlun Zhou, Chuanmin Wang, Aejaz Sayeed, Timothy Block

Published in: Current Hepatology Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

Treatment of chronic hepatitis B infection with nucleos(t)ide analogues induces a significant inhibition of HBV DNA titer. However, reduction of viral DNA load is not an ideal marker to predict sustainable antiviral effect. Circulating HBV RNA has been, recently, explored as a novel biomarker for monitoring viral persistence and the progression of liver disease. This review aims to discuss the characteristics of circulating HBV RNA and to evaluate its applications in hepatitis B infection management.

Recent Findings

HBV RNA is readily detectable in the blood of infected patients. Circulating viral RNA is originated from polyadenylated pgRNA that is packaged in, and secreted with, either naked core particles or virion-like particles. Serum pgRNA could be presented in full length or multiple-spliced forms. The amount and composition of pgRNA in blood can be used to gauge intrahepatic cccDNA transcriptional activity, predict drug response, and reflect liver histologic changes.

Summary

Circulating HBV pgRNA is exclusively transcribed from cccDNA in the liver. As an alternative to liver biopsy, non-invasive measurement of serum HBV RNA in patients receiving antiviral treatment might provide clinicians a safe and effective tool to oversee therapeutic efficacy.
Literature
1.
Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology. 2015;62(6):1893–908.PubMedPubMedCentral
2.
Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284–306.PubMed
3.
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.PubMed
4.
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365(9454):123–9.PubMed
5.
Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology. 2009;49(5 Suppl):S103–11.PubMed
6.
• Ning X, Nguyen D, Mentzer L, Adams C, Lee H, Ashley R, et al. Secretion of genome-free hepatitis B virus--single strand blocking model for virion morphogenesis of para-retrovirus. PLoS Pathog. 2011;7(9):e1002255 Demonstrated that viral DNA synthesis was not required for HBV virion morphogenesis. PubMedPubMedCentral
7.
•• Bai L, Zhang X, Li W, Wu M, Liu J, Kozlowski M, et al. Extracellular HBV RNAs are heterogeneous in length and circulate as virions and capsid-antibody-complexes in chronic hepatitis B patients. J Virol. 2018. https://​doi.​org/​10.​1128/​JVI.​00798-18. Most recent paper revealed that HBV RNA in circulation could be derived from naked core particles.
8.
Ning X, Luckenbaugh L, Liu K, Bruss V, Sureau C, Hu J. Common and distinct capsid and surface protein requirements for secretion of complete and genome-free hepatitis B virions. J Virol. 2018;92(14).
9.
Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018;47(1):43–54.PubMed
10.
Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med. 2017;9(409).
11.
Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N, et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol. 2013;48(10):1188–204.PubMed
12.
Block TM, Zhou T, Anbarasan N, Gish R. Evolving new strategies for the medical management of chronic hepatitis B virus infection. Gastroenterol Hepatol (N Y). 2016;12(11):679–89.
13.
Huang YW, Takahashi S, Tsuge M, Chen CL, Wang TC, Abe H, et al. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. Antivir Ther. 2015;20(4):369–75.PubMed
14.
• Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65(4):700–10 Serum HBV pgRNA was present in virion like particle and the HBV DNA/RNA ratio was reversed after NUC. PubMed
15.
•• Wang J, Yu Y, Li G, Shen C, Meng Z, Zheng J, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol. 2018;68(1):16–24 Solid evidence shown to connect HBV RNA level with cccDNA transcriptional activity and liver histologic changes.
16.
Jones SA, Boregowda R, Spratt TE, Hu J. In vitro epsilon RNA-dependent protein priming activity of human hepatitis B virus polymerase. J Virol. 2012;86(9):5134–50.PubMedPubMedCentral
17.
Jones SA, Clark DN, Cao F, Tavis JE, Hu J. Comparative analysis of hepatitis B virus polymerase sequences required for viral RNA binding, RNA packaging, and protein priming. J Virol. 2014;88(3):1564–72.PubMedPubMedCentral
18.
Patel N, White SJ, Thompson RF, Bingham R, Weiss EU, Maskell DP, et al. HBV RNA pre-genome encodes specific motifs that mediate interactions with the viral core protein that promote nucleocapsid assembly. Nat Microbiol. 2017;2:17098.PubMedPubMedCentral
19.
Hirsch RC, Lavine JE, Chang LJ, Varmus HE, Ganem D. Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as well as for reverse transcription. Nature. 1990;344(6266):552–5.PubMed
20.
Jones SA, Hu J. Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention. Emerg Microbes Infect. 2013;2(9):e56.PubMedPubMedCentral
21.
Jeong JK, Yoon GS, Ryu WS. Evidence that the 5′-end cap structure is essential for encapsidation of hepatitis B virus pregenomic RNA. J Virol. 2000;74(12):5502–8.PubMedPubMedCentral
22.
Cao F, Jones S, Li W, Cheng X, Hu Y, Hu J, et al. Sequences in the terminal protein and reverse transcriptase domains of the hepatitis B virus polymerase contribute to RNA binding and encapsidation. J Viral Hepat. 2014;21(12):882–93.PubMedPubMedCentral
23.
Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479-480:672–86.PubMed
24.
Giersch K, Allweiss L, Volz T, Dandri M, Lutgehetmann M. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2017;66(2):460–2.PubMed
25.
Lam AM, Ren S, Espiritu C, Kelly M, Lau V, Zheng L, et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob Agents Chemother. 2017;61(8):e00680–17.PubMedPubMedCentral
26.
Gerelsaikhan T, Tavis JE, Bruss V. Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. J Virol. 1996;70(7):4269–74.PubMedPubMedCentral
27.
• Kock J, Theilmann L, Galle P, Schlicht HJ. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology. 1996;23(3):405–13 Provided the first evidence that HBV virion particles harbored polyadenylated viral RNA. PubMed
28.
Stoll-Becker S, Repp R, Glebe D, Schaefer S, Kreuder J, Kann M, et al. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients. J Virol. 1997;71(7):5399–407.PubMedPubMedCentral
29.
Baginski I, Chemin I, Bouffard P, Hantz O, Trepo C. Detection of polyadenylated RNA in hepatitis B virus-infected peripheral blood mononuclear cells by polymerase chain reaction. J Infect Dis. 1991;163(5):996–1000.PubMed
30.
Zoulim F, Vitvitski L, Bouffard P, Pichoud C, Rougier P, Lamelin JP, et al. Detection of pre-S1 proteins in peripheral blood mononuclear cells from patients with HBV infection. J Hepatol. 1991;12(2):150–6.PubMed
31.
Rokuhara A, Matsumoto A, Tanaka E, Umemura T, Yoshizawa K, Kimura T, et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol. 2006;41(8):785–90.PubMed
32.
•• Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis. 2016;213(2):224–32 In CHB patients, reduction of serum HBV RNA predicted good response to IFN treatment. PubMed
33.
Su Q, Wang SF, Chang TE, Breitkreutz R, Hennig H, Takegoshi K, et al. Circulating hepatitis B virus nucleic acids in chronic infection: representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin Cancer Res. 2001;7(7):2005–15.PubMed
34.
Hacker HJ, Zhang W, Tokus M, Bock T, Schroder CH. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy. Ann N Y Acad Sci. 2004;1022:271–81.PubMed
35.
Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology. 2007;45(5):1179–86.PubMed
36.
Huang YW, Chayama K, Tsuge M, Takahashi S, Hatakeyama T, Abe H, et al. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. Antivir Ther. 2010;15(2):177–84.PubMed
37.
van Bommel F, Bartens A, Mysickova A, Hofmann J, Kruger DH, Berg T, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61(1):66–76.PubMed
38.
• van Bommel F, van Bommel A, Krauel A, Wat C, Pavlovic V, Yang L, et al. Serum HBV RNA as a predictor of peginterferon alfa-2a (40KD) response in patients with HBeAg-positive chronic hepatitis B. J Infect Dis. 2018; Low-circulating HBV RNA level was associated with HBeAg seroconversion.
39.
Su TS, Lai CJ, Huang JL, Lin LH, Yauk YK, Chang CM, et al. Hepatitis B virus transcript produced by RNA splicing. J Virol. 1989;63(9):4011–8.PubMedPubMedCentral
40.
Ogston CW, Razman DG. Spliced RNA of woodchuck hepatitis virus. Virology. 1992;189(1):245–52.PubMed
41.
Obert S, Zachmann-Brand B, Deindl E, Tucker W, Bartenschlager R, Schaller H. A splice hepadnavirus RNA that is essential for virus replication. EMBO J. 1996;15(10):2565–74.PubMedPubMedCentral
42.
Wang J, Sheng Q, Ding Y, Chen R, Sun X, Chen X, et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. J Hepatol. 2017;S0168–8278(17)32413–3.
43.
Suzuki T, Masui N, Kajino K, Saito I, Miyamura T. Detection and mapping of spliced RNA from a human hepatoma cell line transfected with the hepatitis B virus genome. Proc Natl Acad Sci U S A. 1989;86(21):8422–6.PubMedPubMedCentral
44.
Gunther S, Sommer G, Iwanska A, Will H. Heterogeneity and common features of defective hepatitis B virus genomes derived from spliced pregenomic RNA. Virology. 1997;238(2):363–71.PubMed
45.
• Chen J, Wu M, Wang F, Zhang W, Wang W, Zhang X, et al. Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy. Sci Rep. 2015;5:16459 Comprehensive list of spliced HBV pgRNA. PubMedPubMedCentral
46.
Terre S, Petit MA, Brechot C. Defective hepatitis B virus particles are generated by packaging and reverse transcription of spliced viral RNAs in vivo. J Virol. 1991;65(10):5539–43.PubMedPubMedCentral
47.
Heise T, Sommer G, Reumann K, Meyer I, Will H, Schaal H. The hepatitis B virus PRE contains a splicing regulatory element. Nucleic Acids Res. 2006;34(1):353–63.PubMedPubMedCentral
48.
Chowdhury JB, Roy D, Ghosh S. Identification of a unique splicing regulatory cluster in hepatitis B virus pregenomic RNA. FEBS Lett. 2011;585(20):3348–53.PubMed
49.
Duriez M, Mandouri Y, Lekbaby B, Wang H, Schnuriger A, Redelsperger F, et al. Alternative splicing of hepatitis B virus: a novel virus/host interaction altering liver immunity. J Hepatol. 2017;67(4):687–99.PubMedPubMedCentral
50.
Sheen IS, Tsou YK, Lin SM, Lin CJ, Lin CC, Hsu CW, et al. Nuclear HBcAg and histology activity index as independent predictors of the expression of singly spliced HBV-RNA. J Viral Hepat. 2007;14(1):70–4.PubMed
51.
Ma ZM, Lin X, Wang YX, Tian XC, Xie YH, Wen YM. A double-spliced defective hepatitis B virus genome derived from hepatocellular carcinoma tissue enhanced replication of full-length virus. J Med Virol. 2009;81(2):230–7.PubMed
52.
Rosmorduc O, Petit MA, Pol S, Capel F, Bortolotti F, Berthelot P, et al. In vivo and in vitro expression of defective hepatitis B virus particles generated by spliced hepatitis B virus RNA. Hepatology. 1995;22(1):10–9.PubMed
53.
• Abraham TM, Lewellyn EB, Haines KM, Loeb DD. Characterization of the contribution of spliced RNAs of hepatitis B virus to DNA synthesis in transfected cultures of Huh7 and HepG2 cells. Virology. 2008;379(1):30–7 Spliced pgRNA could be efficiently packaged into nucleocapsid. PubMedPubMedCentral
54.
Huang CC, Kuo TM, Yeh CT, Hu CP, Chen YL, Tsai YL, et al. One single nucleotide difference alters the differential expression of spliced RNAs between HBV genotypes A and D. Virus Res. 2013;174(1–2):18–26.PubMed
55.
Soussan P, Pol J, Garreau F, Schneider V, Le Pendeven C, Nalpas B, et al. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J Infect Dis. 2008;198(2):218–25.PubMed
56.
Lin YM, Chen BF. A putative hepatitis B virus splice variant associated with chronic hepatitis and liver cirrhosis. Virology. 2017;510:224–33.PubMed
57.
Redelsperger F, Lekbaby B, Mandouri Y, Giang E, Duriez M, Desire N, et al. Production of hepatitis B defective particles is dependent on liver status. Virology. 2012;431(1–2):21–8.PubMed
58.
Ziemer M, Garcia P, Shaul Y, Rutter WJ. Sequence of hepatitis B virus DNA incorporated into the genome of a human hepatoma cell line. J Virol. 1985;53(3):885–92.PubMedPubMedCentral
59.
Chen PJ, Chen CR, Sung JL, Chen DS. Identification of a doubly spliced viral transcript joining the separated domains for putative protease and reverse transcriptase of hepatitis B virus. J Virol. 1989;63(10):4165–71.PubMedPubMedCentral
60.
Bayliss J, Lim L, Thompson AJ, Desmond P, Angus P, Locarnini S, et al. Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma. J Hepatol. 2013;59(5):1022–8.PubMed
Metadata
Title
Implications of Circulating Hepatitis B Virus RNA Levels in Assessment of Response to Antiviral Therapy
Authors
Tianlun Zhou
Chuanmin Wang
Aejaz Sayeed
Timothy Block
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 4/2018
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-018-0433-7

Other articles of this Issue 4/2018

Current Hepatology Reports 4/2018 Go to the issue

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Portal Cavernoma Cholangiopathy

Hepatitis B (J Lim, Section Editor)

Long-term Outcomes in Patients with HBV Treated with Antiviral Agents

Hepatitis B (J Lim, Section Editor)

New Advances in Hepatitis B Vaccination for Adults

Fatty Liver Disease (Z Younossi, Section Editor)

The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Current State of Immunotherapy for HCC—Supporting Data and Toxicity Management

Hepatitis B (J Lim, Section Editor)

Update in the Management of Chronic Hepatitis B in Pregnancy
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits